BioCardia (BCDA) said Friday that Emory University School of Medicine in Atlanta has started enrolling patients with ischemic heart failure in the company's ongoing phase 3 CardiAMP HF II trial.
The CardiAMP HF II therapy is a system designed for the harvest, processing and minimally invasive delivery of autologous mononuclear cells to the heart intended to enhance microvascular density and reduce fibrosis, the company said.
The study will compare treatment with CardiAMP therapy to a placebo procedure with all patients on stable guideline directed medical therapy, the company said.
Price: 1.95, Change: +0.02, Percent Change: +1.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.